Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page  Next Page

TRK ligands (these ligands are most commonly nerve growth factor [NGF] for TRKA, brain-derived growth factor [BDGF] or neurotrophin 4 [NT-4] for TRKB, and neurotrophin 3 [NT-3] for TRKC) bind with high affinity to the extracellular domain of the TRK receptor. This leads to receptor dimerisation and autophosphorylation of specific tyrosine residues in the intracellular domain of TRK proteins [1, 2]. This results in activation of signal transduction pathways involved in proliferation, differentiation, and survival (e.g. MAPK, PI3K and PKC pathways) in both normal and neoplastic cells as shown below [1, 2].

Figure 2: TRK Receptor Signalling

Figure 2: TRK Receptor Signalling

With permission from Amatu et al. 2016 [1].

References

  1. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1: e000023.
  2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings